Significant Investment Accelerates Freenome’s Multiomics Platform for the Early Detection of Cancer

SOUTH SAN FRANCISCO, Calif.: SOUTH SAN FRANCISCO, Calif., Jan. 11, 2022 /PRNewswire/ -- Freenome, a privately held biotech company, announced today that Roche has made an investment of $290 million, bringing Freenome's total funding to more than $1.1 billion since the company was founded in 2014. This announcement follows Freenome's...

Click to view original post